19:28 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes 1-6. The agency also approved Epclusa plus ribavirin to treat adults with HCV...
16:11 , May 30, 2018 |  BC Extra  |  Company News

Gilead's Epclusa approved in China for HCV

Gilead Sciences Inc. (NASDAQ:GILD) said China's State Drug Administration (formerly China FDA) approved Epclusa sofosbuvir/velpatasvir to treat adults with chronic HCV genotypes 1-6. The agency also approved Epclusa plus ribavirin to treat adults with HCV...
21:43 , Oct 27, 2017 |  BC Week In Review  |  Company News

Arcturus, JNJ to develop nucleic acids to treat HBV

Arcturus Therapeutics Inc. (San Diego, Calif.) and the Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) partnered to develop and commercialize nucleic acid-based compounds to treat HBV. The companies will use Arcturus' unlocked nucleomonomer...
15:21 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
15:21 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Merck discontinues HCV candidates MK-3682B and MK-3682C

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
21:31 , Sep 29, 2017 |  BC Week In Review  |  Clinical News

China approves HCV drugs from Gilead and AbbVie

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir (GS-7977) to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older. Gilead said the nucleotide analog...
20:49 , Sep 29, 2017 |  BC Extra  |  Clinical News

Merck discontinues HCV candidates

Merck & Co. Inc. (NYSE:MRK) discontinued development of MK-3682B (grazoprevir/ruzasvir/uprifosbuvir) and MK-3682C (ruzasvir/uprifosbuvir), emptying its pipeline of candidates to treat HCV infection. The pharma based its decision on a review of Phase II efficacy data...
23:30 , Sep 26, 2017 |  BC Extra  |  Company News

GSK, Gilead, Shire gain RDPAC membership

China’s R&D-based Pharmaceutical Association Committee (RDPAC) approved new member applications from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Gilead Sciences Inc. (NASDAQ:GILD) and Shire plc (LSE:SHP; NASDAQ:SHPG). In 2013, media outlets reported that GSK voluntarily withdrew its membership...
21:54 , Sep 25, 2017 |  BC Extra  |  Company News

Gilead's Sovaldi gets Chinese approval

Gilead Sciences Inc. (NASDAQ:GILD) said China FDA approved Sovaldi sofosbuvir to treat HCV genotypes 1-6 infection as part of an antiviral treatment regimen in patients ages 12 and older. Gilead said the nucleotide analog HCV...
21:09 , Sep 15, 2017 |  BC Week In Review  |  Company News

J&J drops Achillion HCV deal

Johnson & Johnson (NYSE:JNJ) terminated a 2015 deal with Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) to develop and commercialize HCV therapies, including triplet therapy JNJ-4178 . J&J said it decided to discontinue development of JNJ-4178 “in light...